Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Harvard Business School
Baxter
Medtronic
Merck

Last Updated: December 7, 2021

Volunteer for clinical trials for ubrogepant at ClinicalTrialExchange

DrugPatentWatch Database Preview

Ubrogepant - Generic Drug Details

➤ Subscribe for complete access

« Back to Dashboard

What are the generic sources for ubrogepant and what is the scope of freedom to operate?

Ubrogepant is the generic ingredient in one branded drug marketed by Allergan and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ubrogepant has eighty-six patent family members in forty countries.

One supplier is listed for this compound.

Summary for ubrogepant
International Patents:86
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 20
Clinical Trials: 6
Patent Applications: 38
What excipients (inactive ingredients) are in ubrogepant?ubrogepant excipients list
DailyMed Link:ubrogepant at DailyMed
Recent Clinical Trials for ubrogepant

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AllerganPhase 1
AllerganPhase 3

See all ubrogepant clinical trials

US Patents and Regulatory Information for ubrogepant

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan UBRELVY ubrogepant TABLET;ORAL 211765-002 Dec 23, 2019 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Allergan UBRELVY ubrogepant TABLET;ORAL 211765-002 Dec 23, 2019 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Allergan UBRELVY ubrogepant TABLET;ORAL 211765-002 Dec 23, 2019 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Allergan UBRELVY ubrogepant TABLET;ORAL 211765-002 Dec 23, 2019 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Allergan UBRELVY ubrogepant TABLET;ORAL 211765-001 Dec 23, 2019 RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Allergan UBRELVY ubrogepant TABLET;ORAL 211765-001 Dec 23, 2019 RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Boehringer Ingelheim
Medtronic
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.